Researchers are finding that these medications could help with heart failure, alcohol use disorder, and other conditions
In a cohort of 3731 patients, weight loss of 5%, 10%, and 15% was observed in 63%, 33%, and 14%, respectively, after 56 weeks of treatment (27%, 11%, and 4% with placebo),69 or of an additional 6% at 56 weeks in patients who had already lost 6% through hypocaloric diet and exercise.70 Positive results were also observed in adolescent patients with obesity,71 and in real-life studies substantial weight loss has also been reported.7275 Phase 3 trials with GLP-1 receptor agonists indicated specifically for obesity and overweight
Semaglutide (up to moderate dosing) Ongoing check-ins and support via messaging with your care team Basic guidance and support Medication guidance: Semaglutide: up to 1.0 mg/week Tirzepatide (optional): up to 5 mg/week Optional: Upgrade to tirzepatide + $75/month Standard Protocol $299/month: Guided, structured, and supported Semaglutide (full dosing range) Monthly provider follow-up with body composition analysis Weekly B12 injections included Ongoing clinical support Medication guidance: Semaglutide: up to 1.5 mg/week Tirzepatide (optional): up to 10 mg/week Optional: Upgrade to tirzepatide + $75/month Advanced Protocol $399/month: Comprehensive, high-touch care
Always confirm current pricing on the Priority Meds site before purchasing
Losing weight can be a real challenge, and it often feels like an uphill battle
